Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
44 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Influenza A And B Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Influenza A And B Infections - Pipeline Review, H2 2014', provides an overview of the Influenza A And B Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Influenza A And B Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A And B Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Influenza A And B Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Influenza A And B Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Influenza A And B Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Influenza A And B Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Influenza A And B Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Influenza A And B Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Influenza A And B Infections Overview 6 Therapeutics Development 7 Pipeline Products for Influenza A And B Infections - Overview 7 Pipeline Products for Influenza A And B Infections - Comparative Analysis 8 Influenza A And B Infections - Therapeutics under Development by Companies 9 Influenza A And B Infections - Therapeutics under Investigation by Universities/Institutes 10 Influenza A And B Infections - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Influenza A And B Infections - Products under Development by Companies 13 Influenza A And B Infections - Products under Investigation by Universities/Institutes 14 Influenza A And B Infections - Companies Involved in Therapeutics Development 15 Daiichi Sankyo Company, Limited 15 Beech Tree Labs, Inc. 16 MI.TO. Technology S.r.L. 17 Influenza A And B Infections - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 24 Drug Profiles 26 laninamivir - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 BTL-TML001 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecules to Inhibit Viral RNA Polymerase for Influenza - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Synthetic Peptide for Influenza - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza A and B Virus Infections - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Influenza A And B Infections - Recent Pipeline Updates 33 Influenza A And B Infections - Dormant Projects 36 Influenza A And B Infections - Product Development Milestones 37 Featured News & Press Releases 37 Aug 01, 2014: Biota Reports Top-Line Data From Its Phase 2 "IGLOO" Trial of Laninamivir Octanoate 37 May 08, 2014: Biota Provides Update on BARDA Contract for Laninamivir Octanoate 38 Dec 20, 2013: Biota Reports That Laninamivir Octanoate is Approved for the Prevention of Influenza in Japan 38 Dec 05, 2013: Biota Initiates Dosing in Phase 2 IGLOO Trial of LANI in the Northern Hemisphere 39 Aug 05, 2013: FDA approves supply of GSK's quadrivalent influenza vaccine in US 39 Jun 11, 2013: Biota Initiates Phase II Trial Of Laninamivir Octanoate For Treatment Of Influenza In Adults 39 Jun 10, 2013: Sanofi's New Four-Strain Influenza Vaccine Fluzone Receives FDA Approval For Broad Age Range Of Children And Adults 40 Apr 11, 2013: Sanofi Pasteur Announces Acceptance Of Marketing Authorization Application For Quadrivalent Formulation Of Vaxigrip In Europe 40 Apr 03, 2013: GSK's Four-strain Seasonal Influenza Vaccine Receives Marketing Authorization In Germany And UK 41 Apr 01, 2013: BioCryst Pharma Receives Preliminary Comment Letter From FDA For Peramivir 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 44 Disclaimer 44
List of Tables Number of Products under Development for Influenza A And B Infections, H2 2014 7 Number of Products under Development for Influenza A And B Infections - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Influenza A And B Infections - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 15 Influenza A And B Infections - Pipeline by Beech Tree Labs, Inc., H2 2014 16 Influenza A And B Infections - Pipeline by MI.TO. Technology S.r.L., H2 2014 17 Assessment by Monotherapy Products, H2 2014 18 Number of Products by Stage and Target, H2 2014 20 Number of Products by Stage and Mechanism of Action, H2 2014 22 Number of Products by Stage and Route of Administration, H2 2014 23 Number of Products by Stage and Molecule Type, H2 2014 25 Influenza A And B Infections Therapeutics - Recent Pipeline Updates, H2 2014 33 Influenza A And B Infections - Dormant Projects, H2 2014 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.